Spandidos Publications Logo
  • About
    • About Spandidos
    • Aims and Scopes
    • Abstracting and Indexing
    • Editorial Policies
    • Reprints and Permissions
    • Job Opportunities
    • Terms and Conditions
    • Contact
  • Journals
    • All Journals
    • Oncology Letters
      • Oncology Letters
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Oncology
      • International Journal of Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular and Clinical Oncology
      • Molecular and Clinical Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Experimental and Therapeutic Medicine
      • Experimental and Therapeutic Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Molecular Medicine
      • International Journal of Molecular Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Biomedical Reports
      • Biomedical Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Reports
      • Oncology Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular Medicine Reports
      • Molecular Medicine Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • World Academy of Sciences Journal
      • World Academy of Sciences Journal
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Functional Nutrition
      • International Journal of Functional Nutrition
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Epigenetics
      • International Journal of Epigenetics
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Medicine International
      • Medicine International
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
  • Articles
  • Information
    • Information for Authors
    • Information for Reviewers
    • Information for Librarians
    • Information for Advertisers
    • Conferences
  • Language Editing
Spandidos Publications Logo
  • About
    • About Spandidos
    • Aims and Scopes
    • Abstracting and Indexing
    • Editorial Policies
    • Reprints and Permissions
    • Job Opportunities
    • Terms and Conditions
    • Contact
  • Journals
    • All Journals
    • Biomedical Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Experimental and Therapeutic Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Epigenetics
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Functional Nutrition
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Molecular Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Medicine International
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular and Clinical Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular Medicine Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Letters
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • World Academy of Sciences Journal
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
  • Articles
  • Information
    • For Authors
    • For Reviewers
    • For Librarians
    • For Advertisers
    • Conferences
  • Language Editing
Login Register Submit
  • This site uses cookies
  • You can change your cookie settings at any time by following the instructions in our Cookie Policy. To find out more, you may read our Privacy Policy.

    I agree
Search articles by DOI, keyword, author or affiliation
Search
Advanced Search
presentation
Molecular and Clinical Oncology
Join Editorial Board Propose a Special Issue
Print ISSN: 2049-9450 Online ISSN: 2049-9469
Journal Cover
March-2018 Volume 8 Issue 3

Full Size Image

Sign up for eToc alerts
Recommend to Library

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

Medicine International

An International Open Access Journal Devoted to General Medicine.

Journal Cover
March-2018 Volume 8 Issue 3

Full Size Image

Sign up for eToc alerts
Recommend to Library

  • Article
  • Citations
    • Cite This Article
    • Download Citation
    • Create Citation Alert
    • Remove Citation Alert
    • Cited By
  • Similar Articles
    • Related Articles (in Spandidos Publications)
    • Similar Articles (Google Scholar)
    • Similar Articles (PubMed)
  • Download PDF
  • Download XML
  • View XML
Article

Metformin and aspirin treatment could lead to an improved survival rate for Type 2 diabetic patients with stage II and III colorectal adenocarcinoma relative to non-diabetic patients

  • Authors:
    • Ariella De Monte
    • Davide Brunetti
    • Luigi Cattin
    • Francesca Lavanda
    • Erica Naibo
    • Maria Malagoli
    • Giorgio Stanta
    • Serena Bonin
  • View Affiliations / Copyright

    Affiliations: Unit of Medical Clinic, University Hospital of Cattinara-ASUITS, I‑34149 Trieste, Italy, Department of Medical Sciences, University of Trieste, Cattinara Hospital, I‑34149 Trieste, Italy, Oncology Unit, University Hospital of Cattinara-ASUITS, I‑34149 Trieste, Italy
  • Pages: 504-512
    |
    Published online on: January 11, 2018
       https://doi.org/10.3892/mco.2018.1554
  • Expand metrics +
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
Cited By (CrossRef): 0 citations Loading Articles...

This article is mentioned in:



Abstract

Metformin, the drug of choice in the treatment of type 2 diabetes mellitus (DM2), in addition to aspirin (ASA), the drug prescribed for cardioprotection of diabetic and non‑diabetic patients, have an inhibitory effect on cancer cell survival. The present population‑based study conducted in the province of Trieste (Italy), aimed to investigate the prevalence of DM2 in patients with colorectal adenocarcinoma (CRC) and survival for CRC in diabetic and nondiabetic patients. All permanent residents diagnosed with a CRC between 2004 and 2007 were ascertained through the regional health information system. CRC‑specific and relative survival probabilities were computed for each group of patients defined by CRC stage, presence or absence of DM2 treated with metformin, and presence or absence of daily ASA therapy. A total of 515 CRC patients without DM2 and 156 with DM2 treated with metformin were enrolled in the study. At the time of CRC diagnosis, 71 (14%) nondiabetic and 39 (25%) diabetic patients were taking ASA daily. The five‑year relative survival for stage III CRC was 101% [95% confidence interval (CI)=76‑126] in the 18 patients with DM2 treated with metformin and ASA, 55% (95% CI=31‑78) in the 23 without DM2 treated with ASA, 55% (95% CI=45‑65) in the 150 without DM2 not taking ASA, and 29% (95% CI=13‑45) in the 43 with DM2 treated with metformin, however not with ASA. The findings support the hypothesis of a possible inhibitory effect of metformin and ASA on CRC cells. Randomized controlled trials are required to verify this hypothesis.
View Figures

Figure 1

Figure 2

View References

1 

Binefa G, Rodríguez-Moranta F, Teule A and Medina-Hayas M: Colorectal cancer: From prevention to personalized medicine. World J Gastroenterol. 20:6786–6808. 2014. View Article : Google Scholar : PubMed/NCBI

2 

Guariguata L, Whiting DR, Hambleton I, Beagley J, Linnenkamp U and Shaw JE: Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Res Clin Pract. 103:137–149. 2014. View Article : Google Scholar : PubMed/NCBI

3 

Renehan AG, Yeh HC, Johnson JA, Wild SH, Gale EA and Møller H; Diabetes and cancer research consortium, : Diabetes and cancer (2): Evaluating the impact of diabetes on mortality in patients with cancer. Diabetologia. 55:1619–1632. 2012. View Article : Google Scholar : PubMed/NCBI

4 

Johnson JA, Carstensen B, Witte D, Bowker SL, Lipscombe L and Renehan AG; Diabetes and cancer research consortium, : Diabetes and cancer: Evaluating the temporal relationship between type 2 diabetes and cancer incidence. Diabetologia. 55:1607–1618. 2012. View Article : Google Scholar : PubMed/NCBI

5 

Park HK: Metformin and cancer in type 2 diabetes. Diabetes Metab J. 37:113–116. 2013. View Article : Google Scholar : PubMed/NCBI

6 

Din FV, Valanciute A, Houde VP, Zibrova D, Green KA, Sakamoto K, Alessi DR and Dunlop MG: Aspirin inhibits mTOR signaling, activates AMP-activated protein kinase, and induces autophagy in colorectal cancer cells. Gastroenterology. 142:1504–1515 e3. 2012. View Article : Google Scholar : PubMed/NCBI

7 

O'Brien AJ, Villani LA, Broadfield LA, Houde VP, Galic S, Blandino G, Kemp BE, Tsakiridis T, Muti P and Steinberg GR: Salicylate activates AMPK and synergizes with metformin to reduce the survival of prostate and lung cancer cells ex vivo through inhibition of de novo lipogenesis. Biochem J. 469:177–187. 2015. View Article : Google Scholar : PubMed/NCBI

8 

Edge S, Byrd DR, Compton CC, Fritz AG, Greene FL and Trotti A: AJCC Cancer Staging Manual. Springer-Verlag; New York: 2010

9 

American Diabetes Association, . Diagnosis and classification of diabetes mellitus. Diabetes Care. 37 Suppl 1:S81–S90. 2014. View Article : Google Scholar : PubMed/NCBI

10 

Word Health Organization, . ICD-10 International statistical classification of diseases and related health problems. World Health Organization; Geneva: 2011

11 

Armitage P and Berry G: Statistical methods in medical research. 2nd. Oxford, Boston, Blackwell Scientific, Chicago, III, Distributors, USA: Year Book Medical Publishers, England; 1987

12 

Kalbfleisch JD and Prentice RL: The statistical analysis of failure time data. John Wiley; New York: 1980

13 

Grambsch PM and Therneau TM: Proportional hazards tests and diagnostics based on weighted residuals. Biometrika. 81:515–526. 1994. View Article : Google Scholar

14 

Estève J, Benhamou E and Raymond L: Statistical methods in cancer research. Volume IV. Descriptive epidemiology. IARC Sci Publ. 1994:3021994.

15 

Ederer F, Axtell LM and Cutler SJ: The relative survival rate: A statistical methodology. Natl Cancer Inst Monogr. 6:101–121. 1961.PubMed/NCBI

16 

Patruno V, Venturi M and Roberto S: Demografia in cifre-Tavole di Mortalità. Available from ISTAT. http://www.demo.istat.it/tvm2016

17 

Breslow NE and Day NE: Statistical methods in cancer research. Volume II-The design and analysis of cohort studies. IARC Sci Publ. 1–406. 1987.

18 

Cuzick J: A Wilcoxon-type test for trend. Stat Med. 4:87–90. 1985. View Article : Google Scholar : PubMed/NCBI

19 

Rosato V, Tavani A, Gracia-Lavedan E, Guinó E, Castaño-Vinyals G, Villanueva CM, Kogevinas M, Polesel J, Serraino D, Pisa FE, et al: Type 2 diabetes, antidiabetic medications and colorectal cancer risk: Two case-control studies from italy and spain. Front Oncol. 6:2102016. View Article : Google Scholar : PubMed/NCBI

20 

Siddiqui AA, Spechler SJ, Huerta S, Dredar S, Little BB and Cryer B: Elevated HbA1c is an independent predictor of aggressive clinical behavior in patients with colorectal cancer: A case-control study. Dig Dis Sci. 53:2486–2494. 2008. View Article : Google Scholar : PubMed/NCBI

21 

Campbell PT: The role of diabetes and diabetes treatments in colorectal cancer mortality, incidence and survival. Curr Nutr Rep. 2:37–47. 2013. View Article : Google Scholar

22 

Peeters PJ, Bazelier MT, Leufkens HG, de Vries F and De Bruin ML: The risk of colorectal cancer in patients with type 2 diabetes: Associations with treatment stage and obesity. Diabetes Care. 38:495–502. 2015. View Article : Google Scholar : PubMed/NCBI

23 

Vergès B: Pathophysiology of diabetic dyslipidaemia: Where are we? Diabetologia. 58:886–899. 2015. View Article : Google Scholar : PubMed/NCBI

24 

Sirtori CR, Calabresi L, Pisciotta L, Cattin L, Pauciullo P, Montagnani M, Manzato E, Bittolo Bon G and Fellin R: Effect of statins on LDL particle size in patients with familial combined hyperlipidemia: A comparison between atorvastatin and pravastatin. Nutr Metab Cardiovasc Dis. 15:47–55. 2005. View Article : Google Scholar : PubMed/NCBI

25 

van Diepen JA, Vroegrijk IO, Berbée JF, Shoelson SE, Romijn JA, Havekes LM, Rensen PC and Voshol PJ: Aspirin reduces hypertriglyceridemia by lowering VLDL-triglyceride production in mice fed a high-fat diet. Am J Physiol Endocrinol Metab. 301:E1099–E1107. 2011. View Article : Google Scholar : PubMed/NCBI

26 

Yang G, Wang Y, Feng J, Liu Y, Wang T, Zhao M, Ye L and Zhang X: Aspirin suppresses the abnormal lipid metabolism in liver cancer cells via disrupting an NFκB-ACSL1 signaling. Biochem Biophys Res Commun. 486:827–832. 2017. View Article : Google Scholar : PubMed/NCBI

27 

Eliasson B, Gudbjörnsdottir S, Zethelius B, Eeg-Olofsson K and Cederholm J; National diabetes register (NDR), : LDL-cholesterol versus non-HDL-to-HDL-cholesterol ratio and risk for coronary heart disease in type 2 diabetes. Eur J Prev Cardiol. 21:1420–1428. 2014. View Article : Google Scholar : PubMed/NCBI

28 

Middleton RJ, Foley RN, Hegarty J, Cheung CM, McElduff P, Gibson JM, Kalra PA, O'Donoghue DJ and New JP: The unrecognized prevalence of chronic kidney disease in diabetes. Nephrol Dial Transplant. 21:88–92. 2006. View Article : Google Scholar : PubMed/NCBI

29 

Dörhöfer L, Lammert A, Krane V, Gorski M, Banas B, Wanner C, Krämer BK, Heid IM and Böger CA; DIACORE Study Group, : Study design of DIACORE (DIAbetes COhoRtE) a cohort study of patients with diabetes mellitus type 2. BMC Med Genet. 14:252013. View Article : Google Scholar : PubMed/NCBI

30 

Casanova F, Adingupu DD, Adams F, Gooding KM, Looker HC, Aizawa K, Dove F, Elyas S, Belch JJF, Gates PE, et al: The impact of cardiovascular co-morbidities and duration of diabetes on the association between microvascular function and glycaemic control. Cardiovasc Diabetol. 16:1142017. View Article : Google Scholar : PubMed/NCBI

31 

Notarnicola M, Altomare DF, Correale M, Ruggieri E, D'Attoma B, Mastrosimini A, Guerra V and Caruso MG: Serum lipid profile in colorectal cancer patients with and without synchronous distant metastases. Oncology. 68:371–374. 2005. View Article : Google Scholar : PubMed/NCBI

32 

Gomaraschi M, Ossoli A, Favari E, Adorni MP, Sinagra G, Cattin L, Veglia F, Bernini F, Franceschini G and Calabresi L: Inflammation impairs eNOS activation by HDL in patients with acute coronary syndrome. Cardiovasc Res. 100:36–43. 2013. View Article : Google Scholar : PubMed/NCBI

33 

Din FV, Theodoratou E, Farrington SM, Tenesa A, Barnetson RA, Cetnarskyj R, Stark L, Porteous ME, Campbell H and Dunlop MG: Effect of aspirin and NSAIDs on risk and survival from colorectal cancer. Gut. 59:1670–1679. 2010. View Article : Google Scholar : PubMed/NCBI

34 

Sehdev A and O'Neil BH: The role of aspirin, vitamin D, Exercise, diet, statins and metformin in the prevention and treatment of colorectal cancer. Curr Treat Options Oncol. 16:432015. View Article : Google Scholar : PubMed/NCBI

35 

Zhang ZJ, Zheng ZJ, Kan H, Song Y, Cui W, Zhao G and Kip KE: Reduced risk of colorectal cancer with metformin therapy in patients with type 2 diabetes: A meta-analysis. Diabetes Care. 34:2323–2328. 2011. View Article : Google Scholar : PubMed/NCBI

36 

Liu F, Yan L, Wang Z, Lu Y, Chu Y, Li X, Liu Y, Rui D, Nie S and Xiang H: Metformin therapy and risk of colorectal adenomas and colorectal cancer in type 2 diabetes mellitus patients: A systematic review and meta-analysis. Oncotarget. 8:16017–16026. 2017.PubMed/NCBI

37 

Nie Z, Zhu H and Gu M: Reduced colorectal cancer incidence in type 2 diabetic patients treated with metformin: A meta-analysis. Pharm Biol. 54:2636–2642. 2016. View Article : Google Scholar : PubMed/NCBI

38 

Mei ZB, Zhang ZJ, Liu CY, Liu Y, Cui A, Liang ZL, Wang GH and Cui L: Survival benefits of metformin for colorectal cancer patients with diabetes: A systematic review and meta-analysis. PLoS One. 9:e918182014. View Article : Google Scholar : PubMed/NCBI

39 

Du L, Wang M, Kang Y, Li B, Guo M, Cheng Z and Bi C: Prognostic role of metformin intake in diabetic patients with colorectal cancer: An updated qualitative evidence of cohort studies. Oncotarget. 8:26448–26459. 2017.PubMed/NCBI

40 

Ramjeesingh R, Orr C, Bricks CS, Hopman WM and Hammad N: A retrospective study on the role of diabetes and metformin in colorectal cancer disease survival. Curr Oncol. 23:e116–e122. 2016. View Article : Google Scholar : PubMed/NCBI

41 

Zanders MM, van Herk-Sukel MP, Vissers PA, Herings RM, Haak HR and van de Poll-Franse LV: Are metformin, statin and aspirin use still associated with overall mortality among colorectal cancer patients with diabetes if adjusted for one another? Br J Cancer. 113:403–410. 2015. View Article : Google Scholar : PubMed/NCBI

42 

Saber MM, Galal MA, Ain-Shoka AA and Shouman SA: Combination of metformin and 5-aminosalicylic acid cooperates to decrease proliferation and induce apoptosis in colorectal cancer cell lines. BMC Cancer. 16:1262016. View Article : Google Scholar : PubMed/NCBI

43 

Zhang Y, Guan M, Zheng Z, Zhang Q, Gao F and Xue Y: Effects of metformin on CD133+ colorectal cancer cells in diabetic patients. PLoS One. 8:e812642013. View Article : Google Scholar : PubMed/NCBI

Related Articles

  • Abstract
  • View
  • Download
  • Twitter
Copy and paste a formatted citation
Spandidos Publications style
De Monte A, Brunetti D, Cattin L, Lavanda F, Naibo E, Malagoli M, Stanta G and Bonin S: Metformin and aspirin treatment could lead to an improved survival rate for Type 2 diabetic patients with stage II and III colorectal adenocarcinoma relative to non-diabetic patients. Mol Clin Oncol 8: 504-512, 2018.
APA
De Monte, A., Brunetti, D., Cattin, L., Lavanda, F., Naibo, E., Malagoli, M. ... Bonin, S. (2018). Metformin and aspirin treatment could lead to an improved survival rate for Type 2 diabetic patients with stage II and III colorectal adenocarcinoma relative to non-diabetic patients. Molecular and Clinical Oncology, 8, 504-512. https://doi.org/10.3892/mco.2018.1554
MLA
De Monte, A., Brunetti, D., Cattin, L., Lavanda, F., Naibo, E., Malagoli, M., Stanta, G., Bonin, S."Metformin and aspirin treatment could lead to an improved survival rate for Type 2 diabetic patients with stage II and III colorectal adenocarcinoma relative to non-diabetic patients". Molecular and Clinical Oncology 8.3 (2018): 504-512.
Chicago
De Monte, A., Brunetti, D., Cattin, L., Lavanda, F., Naibo, E., Malagoli, M., Stanta, G., Bonin, S."Metformin and aspirin treatment could lead to an improved survival rate for Type 2 diabetic patients with stage II and III colorectal adenocarcinoma relative to non-diabetic patients". Molecular and Clinical Oncology 8, no. 3 (2018): 504-512. https://doi.org/10.3892/mco.2018.1554
Copy and paste a formatted citation
x
Spandidos Publications style
De Monte A, Brunetti D, Cattin L, Lavanda F, Naibo E, Malagoli M, Stanta G and Bonin S: Metformin and aspirin treatment could lead to an improved survival rate for Type 2 diabetic patients with stage II and III colorectal adenocarcinoma relative to non-diabetic patients. Mol Clin Oncol 8: 504-512, 2018.
APA
De Monte, A., Brunetti, D., Cattin, L., Lavanda, F., Naibo, E., Malagoli, M. ... Bonin, S. (2018). Metformin and aspirin treatment could lead to an improved survival rate for Type 2 diabetic patients with stage II and III colorectal adenocarcinoma relative to non-diabetic patients. Molecular and Clinical Oncology, 8, 504-512. https://doi.org/10.3892/mco.2018.1554
MLA
De Monte, A., Brunetti, D., Cattin, L., Lavanda, F., Naibo, E., Malagoli, M., Stanta, G., Bonin, S."Metformin and aspirin treatment could lead to an improved survival rate for Type 2 diabetic patients with stage II and III colorectal adenocarcinoma relative to non-diabetic patients". Molecular and Clinical Oncology 8.3 (2018): 504-512.
Chicago
De Monte, A., Brunetti, D., Cattin, L., Lavanda, F., Naibo, E., Malagoli, M., Stanta, G., Bonin, S."Metformin and aspirin treatment could lead to an improved survival rate for Type 2 diabetic patients with stage II and III colorectal adenocarcinoma relative to non-diabetic patients". Molecular and Clinical Oncology 8, no. 3 (2018): 504-512. https://doi.org/10.3892/mco.2018.1554
Follow us
  • Twitter
  • LinkedIn
  • Facebook
About
  • Spandidos Publications
  • Careers
  • Cookie Policy
  • Privacy Policy
How can we help?
  • Help
  • Live Chat
  • Contact
  • Email to our Support Team